Methylthioadenosine reverses brain autoimmune disease
Moreno B, Hevia H, Santamaria M, Sepulcre J, Muñoz J, García‐Trevijano E, Berasain C, Corrales F, Avila M, Villoslada P. Methylthioadenosine reverses brain autoimmune disease. Annals Of Neurology 2006, 60: 323-334. PMID: 16786535, DOI: 10.1002/ana.20895.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge of OnsetAmyloid beta-Protein PrecursorAnimalsCytokinesDisease Models, AnimalDose-Response Relationship, DrugDrug InteractionsEncephalomyelitis, Autoimmune, ExperimentalFemaleHumansImmunologic FactorsLymphocytesMacrophagesMaleMiddle AgedMultiple SclerosisNitric Oxide Synthase Type IIPhytohemagglutininsRatsRats, Inbred LewReverse Transcriptase Polymerase Chain ReactionRNA, MessengerStatistics, NonparametricThionucleosidesConceptsExperimental autoimmune encephalomyelitisAutoimmune diseasesChronic relapsing EAET cell activation in vivoAcute experimental autoimmune encephalomyelitisExperimental autoimmune encephalomyelitis animalsPeripheral blood mononuclear cellsMultiple sclerosisChronic EAE modelHealthy control subjectsInhibiting brain inflammationBlood mononuclear cellsProduction of antiinflammatory cytokinesRodent experimental autoimmune encephalomyelitisImmunomodulatory activityPrevention of inhibitorsTranscription factor nuclear factor-kappaB.Cytokine gene expressionNuclear factor-kappaB.Real-time polymerase chain reactionReduced brain damageT cell signalingMultiple sclerosis patientsAutoimmune encephalomyelitisEAE model